文献速递主动脉疾病

主动脉瘤自然进展不受合并恶性肿瘤及化疗影响

Aortic Aneurysm Natural Progression is Not Influenced by Concomitant Malignancy and Chemotherapy.
PubMed 文献 · Ann Vasc Surg · 2020-09-11

本研究回顾性纳入2005至2017年间的主动脉瘤患者,比较合并恶性肿瘤(159例,172个动脉瘤)与无恶性肿瘤(127例,149个动脉瘤)患者的动脉瘤进展。结果显示两组动脉瘤生长速率相似,无恶性肿瘤患者初始尺寸更大、接受修复更多;抗代谢化疗轻微加速生长,拓扑异构酶抑制剂可能需更早修复。

要点

  • 合并恶性肿瘤的主动脉瘤患者初始尺寸更小,生长速率与无恶性肿瘤者相似。
  • 抗代谢化疗轻微加速动脉瘤生长,拓扑异构酶抑制剂使用者可能需更早修复。
  • 合并恶性肿瘤患者可遵循标准动脉瘤监测方案,建议先治疗恶性肿瘤再修复小动脉瘤。

核心结论

  • 合并恶性肿瘤的小主动脉瘤初始尺寸更小、生长速率相似、干预更少、破裂和急性夹层更少。
  • 抗代谢化疗轻微加速动脉瘤生长,拓扑泊酶抑制剂使用者可能需更早修复。
  • 合并恶性肿瘤患者可自信地按照标准机构动脉瘤监测方案治疗,建议先治疗恶性肿瘤再修复小动脉瘤。

研究设计与样本

  • 回顾性研究,利用机构数据库识别2005至2017年间的主动脉瘤患者,包括合并与不合并恶性肿瘤者。
  • 纳入标准包括完整的化疗记录,以及治疗前、中、后至少3次多平面轴位/冠状位影像或超声检查,无恶性肿瘤患者需2次检查。
  • 共纳入159例(172个动脉瘤)合并恶性肿瘤患者和127例(149个动脉瘤)无恶性肿瘤患者。
  • 采用倾向性匹配、Cox回归和线性回归、Kaplan-Meier生存分析。

主要发现

  • 无恶性肿瘤患者动脉瘤 grew to larger sizes(4.43 ± 0.96 vs. 4.14 ± 1.00, P = 0.008),中位生长速率相似(0.12 vs. 0.12 cm/year, P = 0.090)。
  • 无恶性肿瘤患者更常见不典型形态特征(14.1% vs. 0.6%, P < 0.001),更常接受修复(22.1% vs. 8.7%, P = 0.001),因破裂需急诊修复更常见(5.4% vs. 0.0%, P = 0.087)。
  • Cox回归识别初始主动脉尺寸≥4.0 cm(HR 3.028)、AAA(HR 2.146)、慢性主动脉表现(HR 3.589)和使用拓扑异构酶抑制剂(HR 2.694)为相关因素。
  • 线性回归显示抗代谢化疗(β 0.170)、初始主动脉尺寸(β 0.086)和腹主动脉位置(β 0.139, all P < 0.002)预测生长速率增加。

关键数值与推荐

  • 合并恶性肿瘤患者平均年龄74.4 ± 9.8岁,白人66.8%,男性70.3%,高血压71.1%,当前吸烟24.5%,冠状动脉粥样硬化病26.2%,AAA 71.0%。
  • 最常见恶性肿瘤为肺癌(48.4%),多数化疗方案包含铂类烷化剂和同期抗代谢药(56.0%)。
  • 总体中位随访时间28.2(范围3.1-174.4)个月。

临床怎么用

  • 合并恶性肿瘤的主动脉瘤患者可按照标准机构动脉瘤监测方案进行随访。
  • 建议先治疗恶性肿瘤,再修复小主动脉瘤,因为其行为与无恶性肿瘤患者相似。
  • 使用拓扑异构酶抑制剂的患者可能需要更早考虑修复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortic aneurysms occur concomitantly with malignancy in approximately 1.0-17.0% of patients. There is little published information regarding the effects of subsequent oncological therapies on aortic aneurysm growth. The aim of this study was to determine the effects of chemoradiation therapies on the natural progression of small abdominal aortic aneurysm (AAA), thoracic aortic aneurysm, and thoracoabdominal aortic aneurysm. METHODS: Patients with aortic aneurysms with and without malignancy between 2005 and 2017 were identified within institutional databases using Current Procedural Terminology and International Classification of Disease codes. Inclusion criteria included complete chemotherapy documentation, a minimum of 3 multiplanar axial/coronal imaging or ultrasonography before, during, and after receiving therapy or 2 studies for patients without malignancy. Propensity matching, Cox and linear regression, and Kaplan-Meier survival analyses were performed. RESULTS: A total of 159 (172 aneurysms) patients with malignancy and 127 (149 aneurysms) patients without malignancy were included. Average patient demographics were 74.4 ± 9.8-years-old, Caucasian (66.8%), male (70.3%), with hypertension (71.1%), current smoking (24.5%), coronary atherosclerotic disease (26.2%), and AAA (71.0%). The most common malignancy was lung cancer (48.4%) with most chemotherapy regimens including a platinum-based alkylating agent and concurrent antimetabolite (56.0%). The overall median follow-up time was 28.2 (range 3.1-174.4) months. Aortic aneurysms in patients without malignancy grew to larger sizes (4.43 ± 0.96 vs. 4.14 ± 1.00, P = 0.008) with similar median growth rates (0.12 vs. 0.12 cm/year, P = 0.090), had more atypical morphologic features (14.1% vs. 0.6%, P < 0.001), more frequently underwent repair (22.1% vs. 8.7%, P = 0.001), and more frequently required emergency repair for rupture (5.4% vs. 0.0%, P = 0.087). Cox regression identified initial aortic size ≥4.0 cm (hazard ratio [HR] 3.028), AAA (HR 2.146), chronic aortic findings (3.589), and the use of topoisomerase inhibitors (HR 2.694). Linear regression demonstrated increased growth rates predicted by antimetabolite chemotherapy (β 0.170), initial aortic size (β 0.086), and abdominal aortic location (β 0.139, all P < 0.002). CONCLUSIONS: Small aortic aneurysms with concomitant malignancies are discovered at smaller initial sizes, grow at similar rates, require fewer interventions, and have fewer ruptures and acute dissections than patients without malignancy. Antimetabolite therapies modestly accelerate aneurysmal growth, and patients receiving topoisomerase inhibitors may require earlier repair. Patients with concomitant disease can be confidently treated according to standard institutional aneurysm surveillance protocols. Overall, we recommend treatment of the malignancy before small aortic aneurysm repair as these aneurysms behave similarly to those in patients without malignancy.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Maxwell DW, Kenney L, Sarmiento JM, et al. Aortic Aneurysm Natural Progression is Not Influenced by Concomitant Malignancy and Chemotherapy. Ann Vasc Surg. 2020. PMID: 32927035. doi:10.1016/j.avsg.2020.08.137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。